南模生物12月24日获融资买入403.02万元，融资余额6368.59万元

Group 1 - The core viewpoint of the news is that Nanmo Biological has shown a mixed performance in financing activities and stockholder dynamics, with notable growth in revenue and net profit year-on-year [1][2][3] Group 2 - As of December 24, Nanmo Biological's stock price increased by 0.86%, with a trading volume of 20.25 million yuan. The financing buy-in amount was 4.03 million yuan, while the financing repayment was 4.46 million yuan, resulting in a net financing buy-in of -0.43 million yuan [1] - The total financing and securities balance for Nanmo Biological reached 63.69 million yuan, accounting for 1.94% of the circulating market value, which is above the 60th percentile level over the past year [1] - The company has not engaged in any short selling activities on December 24, with a short selling balance of 0.00 yuan, indicating a high position relative to the past year [1] Group 3 - As of September 30, the number of shareholders for Nanmo Biological was 6,687, an increase of 2.53% from the previous period, while the average circulating shares per person decreased by 2.47% to 11,658 shares [2] - For the period from January to September 2025, Nanmo Biological achieved a revenue of 303 million yuan, representing a year-on-year growth of 14.29%, and a net profit attributable to shareholders of 26.76 million yuan, which is a significant increase of 276.14% year-on-year [2] Group 4 - Nanmo Biological has distributed a total of 30.04 million yuan in dividends since its A-share listing, with 10.00 million yuan distributed over the past three years [3] - As of September 30, 2025, Tianhong Medical Health A became the tenth largest circulating shareholder with 377,400 shares, while Rongtong Health Industry Flexible Allocation Mixed A/B exited the top ten circulating shareholders [3]